Mounjaro contains the same active ingredient as Zepbound (tirzepatide) but is Health Canada–approved for type 2 diabetes, not as a standalone weight loss treatment. However, significant weight loss is a well-documented effect, and it is sometimes prescribed off-label for weight management.
Mounjaro mimics the GLP-1 hormone, which slows the passage of food through the stomach, helping people feel fuller longer, and promotes insulin release to help reduce blood sugar. As a dual GLP-1/GIP agonist, it works on two hunger-signalling hormones simultaneously.
Starting at 2.5 mg once weekly for the first 4 weeks, then increased to 5 mg, and may be increased up to 15 mg once weekly if needed.